

REMARKS

Claims 34, 42, 45, 66, 69, 77, 85, 86, and 88-92 were examined in the Office Action under reply. Claims 45, 69 and 88 were indicated as allowable and the remaining claims were rejected under 35 U.S.C. §103(a). In particular, the Office notes “[t]he prior art does not appear to teach or suggest the vector of SEQ ID NO: 6.” Office Action, page 5. Applicants assume claim 92 is also allowable as there were no stated art rejections directed to claim 92, and claim 92 also pertains to the vector of SEQ ID NO:6.

Applicants assert for reasons of record that all of the pending claims distinguish over the art. However, solely in an effort to advance prosecution, claims 34, 42, 43, 66-68, 77, 81, 82, 85, 86 and 89-91 have been canceled. Cancellation of the claims is made without prejudice, without intent to abandon any originally claimed subject matter, and without intent to acquiesce in any rejection of record. Applicants expressly reserve the right to file one or more continuing applications hereof containing the canceled claims.

Claims 88 and 92 have been amended for antecedent basis purposes. Withdrawn claims 80, 83 and 84 have been amended to depend from allowable claim 92. Additionally, claim 80 has been amended to incorporate recitations from canceled claim 82. Accordingly, rejoinder of method claims 80, 83 and 84 is respectfully requested.

CONCLUSION

In light of the above remarks, applicants submit the present application is fully in condition for allowance. Early notice to that effect is earnestly solicited.

If the Examiner contemplates other action, or if a telephone conference would expedite allowance of the claims, applicants invite the Examiner to contact the undersigned.


The Commissioner is hereby authorized to charge any fees and credit any overpayment of fees which may be required under 37 C.F.R. §1.16, §1.17, or §1.21, to Deposit Account No. 18-1648.

Please direct all further written communications regarding this application to:

Mark Seka
Novartis Vaccines & Diagnostics, Inc.
Intellectual Property - R338
P. O. Box 8097
Emeryville, CA 94662-8097
Tel: (510) 923-2706
Fax: (510) 655-3542

Respectfully submitted,

Date: 5/13/08

By: 
Roberta L. Robins
Registration No. 33,208

Novartis Vaccines & Diagnostics, Inc.
Intellectual Property - R338
P. O. Box 8097
Emeryville, CA 94662-8097